Loading data for DRMAW — first visit, this takes a few seconds.
Dermata Therapeutics, Inc. (DRMAW)
NasdaqCM: DRMAW
· Real-Time Price · USD
0.00
+0.00 (n/a)
At close: Aug 17, 2026, 3:53 PM
The price, the headline numbers and the latest news, in one place.
Dermata Therapeutics, Inc. (DRMAW) Stock Price, Analysis & Data
No data available
| Bid | 0 |
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.37M |
| 0.66 | |
| -2.16 | |
| n/a | |
| n/a | |
| P/B (ttm) | 0.00 |
| P/S (ttm) | 0.00 |
| Earnings Date | n/a |
| Ask | 0 |
| Volume | 146,059 |
| Avg. Volume (20D) | n/a |
| Open | 0.02 |
| Previous Close | 0.00 |
| Day's Range | 0.00 - 0.00 |
| 52-Week Range | 0.00 - 0.00 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DRMAW
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California...
IPO Date Jul 17, 2026
Employees 9
Stock Exchange NasdaqCM
Ticker Symbol DRMAW
Website https://www.dermatarx.com
Financial Performance
In 2025, Dermata Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -7.56M, a decrease of -38.49%.
Financial StatementsEarnings Surprise
Dermata Therapeutics has released their quarterly earnings on Invalid Date:
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of misses estimates by , with NaN% YoY growth.